Effect of immunotherapy or anti-angiogenesis therapy combined with chemotherapy for advanced triple-negative breast cancer: A real-world retrospective study

• Published in: International immunopharmacology Vol. 143; no. Pt 3; p. 113516
• Main Authors: Chen, Limin, Zhou, Hanxing, Wu, Huailiang, Lu, Qianyi, Huang, Jiajia, Wang, Shusen
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 25.12.2024
• Subjects: Adult; Aged; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - therapeutic use; Anti-angiogenic therapy; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chemotherapy; Combination therapy; Female; Humans; Immune Checkpoint Inhibitors - adverse effects; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Immunotherapy - methods; Middle Aged; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - mortality; Triple-negative breast cancer; Chemotherapy; Anti-angiogenic therapy; Combination therapy; Immunotherapy; Triple-negative breast cancer

•ICI-chemo demonstrated better clinical survival benefit than anti-angio-chemo for the first-line treatment of advanced TNBC.•ICI-chemo/anti-angio-chemo is a promising therapeutic option for the second line or later therapy of advanced TNBC.•No difference between the ICI-chemo and the anti-angio-che...